Rituxan and Hepatic necrosis - a phase IV clinical study of FDA data

Summary:

Hepatic necrosis is reported as a side effect among people who take Rituxan (rituximab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Leukeran, and have Anaemia haemolytic autoimmune.

The phase IV clinical study analyzes which people have Hepatic necrosis when taking Rituxan. It is created by eHealthMe based on reports of 64,282 people who have side effects when taking Rituxan from the FDA, and is updated regularly.

What is Rituxan?

Rituxan has active ingredients of rituximab. It is often used in rheumatoid arthritis. eHealthMe is studying from 64,792 Rituxan users. Check the latest studies of Rituxan.

What is Hepatic necrosis?

Hepatic necrosis (large portions of liver die off due to severe liver disease) is found to be associated with 588 drugs and 744 conditions by eHealthMe. Check the latest studies of Hepatic necrosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

64,282 people reported to have side effects when taking Rituxan.
Among them, 12 people (0.02%) have Hepatic necrosis.

Among these 12 people:

How long have people been on Rituxan when they have Hepatic necrosis? *

What is the gender of people who have Hepatic necrosis when taking Rituxan? *

female: 50 %
male: 50 %

What is the age of people who have Hepatic necrosis when taking Rituxan? *

What are other drugs people take besides Rituxan? *

What are other side effects people have besides Hepatic necrosis? *

Fever: 9 people, 75.00%
Hepatic Failure (liver failure): 6 people, 50.00%
Liver Function Tests Nos Abnormal: 5 people, 41.67%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 5 people, 41.67%
Hepatomegaly (abnormal enlargement of the liver): 4 people, 33.33%
Blood Creatinine Increased: 4 people, 33.33%
Confusion: 4 people, 33.33%
Haemoglobin Decreased: 4 people, 33.33%
International Normalised Ratio Increased: 4 people, 33.33%
Gallstones (stone formation by bile component): 4 people, 33.33%

What are the existing conditions these people have? *

Lymphoma (cancer that begins in immune system cells): 1 person, 8.33%
Anaemia Haemolytic Autoimmune (a condition in which the immune system attacks the red blood cells, resulting in fewer of these oxygen-transporting cells): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Rituxan and have Hepatic necrosis?

- Check whether Hepatic necrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rituxan:

Rituxan (64,792 reports)

Browse all side effects of Rituxan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic necrosis:

Hepatic necrosis (588 drugs)

Browse all the conditions that are associated with Hepatic necrosis:

Hepatic necrosis (744 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rituximab (the active ingredients of Rituxan) and Rituxan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.